Company profile


Time Milestone

November
2000


August
2001

November
2001


March
2002


March
2002


April
2002

August
2002



October
2002



June
2003


July
2003


June
2004


July
2005


July
2005


August
2005

GalPharma Co., Ltd., was established in Suginami-ku, Tokyo, for the research and development of diagnostic and therapeutic agents based on galectin, a type of protein.

The head office was moved to Miki-cho, Kagawa.


Collaborative research was started with the Department of Immunology and Immunopathology and the Department of Endocrinology at Kagawa Medical University (now the Faculty of Medicine, Kagawa University).

A partnership was formed with Fuso Pharmaceutical Industries, Ltd., for the research and development of diagnostic agents for cancer metastasis and therapeutic agents for cancer based on galectin-9 and related substances.

Our development of a cancer metastatic prognosis diagnosing kit was selected as part of the 2001 short-term regional new business consortium research and development project by Shikoku Bureau of Economy, Trade & Industry.

The head office was moved to Takamatsu-shi, Kagawa.


Our feasibility study on the development of curative agents for cancer by induction of protein expression in vivo was selected as part of the 2002 problem-oriented new technology feasibility study project by the Japan Small and Medium Enterprise Corporation.

The endowed chair, Department of Cell Regulation, was established at Kagawa Medical University (now the Faculty of Medicine, Kagawa University) to fund expression analysis of galectins and research and development in the field of cell regulation and function.

Our development of neutrophil activity modulators on the basis of galectin was selected as part of the 2003 Kagawa innovative technology research and development grant project.

Our development of the high-sensitivity galectin protein detection kit was selected as part of the 2003 medium and small business innovation grant project by Shikoku Bureau of Economy, Trade & Industry.

Our development of neutrophil activity modulators on the basis of galectin was selected as part of the 2004 Kagawa innovative technology research and development grant project.

Our development of the high-sensitivity galectin protein detection kit was selected as part of the 2003 medium and small business innovation grant project by Shikoku Bureau of Economy, Trade & Industry.

Our development of new tumor markers on the basis of carbohydrate chain analysis was selected as part of the 2005 regional new business consortium research and development project (for medium and small businesses).

Our development of tumor infiltration and metastasis inhibitors targeting Wnt5a and Ror2 signal transduction system and galectin-9 and new diagnostic methods was selected as part of the 2005 Hyogo Center of Excellence Program Promotion Project.

@